In a stratified analysis based on the cancer types, we found that the HLA-G 14-bp Ins/Del polymorphism was significantly associated with a reduced EC risk in the dominant model (Ins/Del + Ins/Ins vs.Del/Del: OR = 0.66, CI = 0.45–0.96, P=0.029) and in the allelic comparisons model (Ins vs. Del: OR = 0.81, CI = 0.67–0.97, P=0.022). The gene discussed is HLA-G; the disease is cancer.